INTRODUCTION
============

The pathogenetic role of natural regulatory T cells (Tregs) in HIV infection is still ill defined. Treg-induced suppression can be deleterious for the development of an efficient anti-HIV specific immune response, but it may be also helpful in preventing an inappropriate immune activation \[[@R1],[@R2]\]. Indeed, the increase of Tregs in HIV^+^ patients has been linked to a reduced immune activation and low viral load \[[@R2]\] but the accumulation of Tregs in lymphoid tissues was also found to be associated with a high viremia \[[@R3]\], both in infected patients and simian immunodeficiency virus-infected macaques \[[@R4]\]. The data about the frequencies of circulating Tregs in HIV^+^ patients are conflicting \[[@R5]-[@R7]\], most likely because of the different biological samples (whole blood *vs* separated peripheral blood cells) or patients being analyzed. For example, one study demonstrated a lower Treg frequency in viremic patients compared with aviremic subjects \[[@R8]\], while another showed an increased Treg frequency only in the viremic HIV^+^ individuals with a late-stage disease and with a reduced CD4^+^ cell number \[[@R9]\]. Another explanation of these discrepancies relies on the different procedures employed for the characterization of Tregs: initially, they have been identified with a suboptimal CD4^+^CD25^high^ phenotyping \[[@R10],[@R11]\]; then, using the more universally accepted CD4^+^CD25^+^FOXP3^+^ phenotype, which requires an intracellular staining \[[@R3],[@R12]\]; more recently, Tregs have also been identified as CD4^+^CD25^+^CD127^low/−^ cells because of a low expression of the IL-7 receptor (CD127)and of a tight correlation with CD4^+^CD25^+^FOXP3^+^ cells \[[@R13]-[@R15]\].

The heterogeneity of the Treg subpopulations \[[@R16]\], which include the naïve- (CD45RA^+^) and memory-like (CD45RA^−^) subpopulations \[[@R13],[@R17]\], should be also taken into account. Among naïve Tregs, the expression of the CD31 antigen, which identifies T cells recently released from the thymus \[[@R18]\], allows the identification of "recent thymic emigrants" (RTE)-Tregs, which are important in the context of Treg homeostasis \[[@R19],[@R20]\]. Memory Tregs, similarly to conventional central memory (T~CM~) and effector memory (T~EM~) T cells, can be further divided into central memory-like (Treg~CM~) and effector memory-like (Treg~EM~) on the basis of the chemokine receptor 7 (CCR7) expression \[[@R21],[@R22]\]. According to Menning *et al.* \[[@R23]\] the expression of the homing receptor CCR7 differentially regulates the *in vivo* function of Tregs: Treg~CM~ control the onset of immune responses in lymphoid organs like conventional CD4^+^ T~CM~ cells, while Treg~EM~ modulate the suppressive phase in peripheral tissues \[[@R22]\]. Finally, according to the variable expression of FOXP3 and CD25 in CD45RA^+^ or CD45RA^−^ cells, it is possible to identify two further subsets of Tregs endowed with different regulatory potential: resting Tregs (called rTregs \[[@R20]\] or naïve-like nTregs \[[@R24]\], depending on the study), which display the reduced suppressive capacity and properties of naïve cells, and activated Tregs (aTregs), which have an increased suppressive capacity and can be assimilated to memory-like Tregs \[[@R17],[@R20],[@R24]\].

To our knowledge, no studies have analyzed all these subsets (naïve Tregs, RTE-Tregs, Treg~CM~, Treg~EM~, rTregs, and aTregs) in HIV-infected individuals. Therefore, we quantified all Treg subpopulations in two groups of HIV-infected patients with similar CD4^+^ cell counts, one viremic but not requiring treatment because of a relatively conserved number of CD4^+^ cells and the other aviremic because of a long lasting (more than 6 years) combined antiretroviral therapy (cART), in order to investigate whether the modulation of the different Treg subsets could help explaining the preserved immunity observed in the first group of patients.

PATIENTS AND METHODS
====================

Patients
--------

Two groups of patients were investigated. The first included 22 viremic HIV^+^ patients, who did not require therapy according to the current guidelines because of a sufficiently conserved CD4^+^ cell count, and because they did not manifest clinical signs of opportunistic infections or tumours. The second comprised 30 aviremic patients (plasma HIV-1 RNA \<37 copies/mL for more than 6 years) under-going long-term (\>6 years) combination antiretroviral therapy (cART) with zidovudine, lamivudine, and lopinavir/ ritonavir, or tenofovir, lamivudine, and efavirenz, in whom the CD4^+^ cellular immunity was partially restored by stable therapy (Table **[1](#T1){ref-type="table"}**). The study was conducted in accordance with good clinical practice (ICH-E6). The trial and amendments received approval by the institutional review board/independent ethics committee (resolution of n. 33 of March 11, 2011), and the patients provided written informed consent. Blood samples from 15 HIV^−^ healthy donors (HD) were used as controls.

Flow Cytometry Analysis
-----------------------

Treg subsets were determined by six-color flow cytometry on fresh whole blood obtained from untreated, cART-treated patients, and HD. Briefly, 100 μL of whole blood were stained with various combinations of optimal staining concentrations (previously determined by titrations) of allophycocyanin-H7 anti-CD4, fluorescein isothiocyanate anti-CD45RA (BD Pharmingen, Heidelberg, Germany), phycoerythrin anti-CD25, peridin-clorophyll protein-Cy5.5 anti-CCR7 (BioLegend, San Diego, CA), phycoerythtin-Cy7 anti-CD127 (eBioscience, San Diego, CA), and allophycocyanin anti-CD31 (Miltenyi Biotec, Bergisch Gladbach, Germany). The staining lasted for 15 minutes at room temperature and was followed by red blood cells lysis with BD Pharm Lyse™ lysing solution (BD Pharmingen). Data were collected using a BD FACSCanto II cytometer and analyzed with the FACSDiva software (BD Biosciences, San Jose, CA). Naïve, T~CM,~ and T~EM~ cells were respectively identified as CD4^+^CD45RA^+^CCR7^+^, CD4^+^CD45RA^−^CCR7^+^, and CD4^+^CD45RA^−^CCR7^−^ lymphocytes. Tregs, which were cells with a CD4^+^CD25^+^CD127^low/−^ phenotype, were divided into: naïve Tregs, which were cells with a CD45RA^+^CCR7^+^phenotype; Treg~CM~, which were CD45RA^−^CCR7^+^cells; and Treg~EM~, which were CD45RA^−^CCR7^−^ cells (Fig. **[1A](#F1){ref-type="fig"}**) \[[@R13]-[@R15]\]. RTE-Tregs were cells with a CD4^+^CD25^+^CD127^low/−^CD45RA^+^CCR7^+^CD31^+^ phenotype \[[@R19],[@R20]\]. Finally, the subsets of nTregs and aTregs were recog-nized as cells displaying, respectively, the CD4^+^CD45RA^+^CD25^+^ and CD4^+^CD45RA^−^CD25^high^ phenotypes (Fig. **[1B](#F1){ref-type="fig"}**), whereas CD4^+^CD45RA^-^CD25^+^ were not considered in the analysis because they represent effector-like, cytokine secreting cells lacking suppressive capacity \[[@R20],[@R24]\].

Statistical Analysis
--------------------

ANOVA or the Kruskal-Wallis test, according to the normality of the data distribution, followed by the Dunn's post-hoc test were employed to compare the percentages and number of Tregs and Treg subpopulations (which are reported herein as medians and depicted as box-and-whisker plots). Analysis of covariance was also employed to adjust for the effect of the age. The Spearman's test was used to assess correlations. Statistical significance was set at p\<0.05.

RESULTS AND DISCUSSION
======================

The percentage and number of the total Tregs, identified as CD4^+^CD25^+^CD127^low/−^ cells, did not differ in the untreated viremic and long-term treated aviremic patients from that of HD (7.8% *vs* 8.5% *vs* 8.6% and 47 cells/µL *vs* 45 cells/µL *vs* 55 cells/µL; p=NS). A similar result was found when an analysis of covariance was performed to adjust for the effects of age (not shown). Differently from the above, by analysing the Treg subsets we found a redistribution of these cells in the untreated viremic patients, with an increase in the proportion (but not in the number) of naïve Tregs at the detriment of memory Tregs and, in particular, of the Treg~CM~cells. Indeed, these cells were significantly decreased both in terms of percentage (Fig. **[1C](#F1){ref-type="fig"}**) and total number (not shown), while only the total number, and not the percentage, of Treg~EM~ was reduced (data not shown).

A differential redistribution of Treg subsets was also found when these cells were identified as nTregs and aTregs (Fig. **[1D](#F1){ref-type="fig"}**), which display features of naive-like and memory-like Tregs, respectively \[[@R17],[@R20],[@R24]\]. We found, in fact, a significant increase of nTregs only in the untreated viremic patients and a strong positive correlation between the percentage of naive Tregs and nTregs, both when data were analyzed altogether (r=0.83, p\<0.001) and in each patient group (Fig. **[1E](#F1){ref-type="fig"}**). Likewise, positive correlations were present between the total percentage of memory Tregs (Treg~EM\ +~Treg~CM~) and aTregs (Appendix Fig. **[1](#APF1){ref-type="fig"}**). These changes in the Treg subset redistribution were not due to the known effects of age on new T-cell production because the analysis of covariance did not detect any significant group-specific age-mediated effect (p=0.31), but confirmed that the population of naïve Treg cells was more represented in the untreated than in cART-treated patients and HD (age-adjusted means: 45.8% *vs* 36.6% *vs* 32.2%, respectively; p\<0.001).

The increased naive Tregs were not likely to result from an increased output of naive Tregs from the thymus because RTE-Tregs, which represent the subset of Tregs recently released from the thymus \[[@R19],[@R20]\], were not different in the three groups (4% *vs* 4% *vs* 4%, and 4.7 cells/µL *vs* 8.5 cells/µL *vs* 6 cells/µL; p=NS), even if data were age-adjusted (not shown). Thus, the present findings may be explained by a slow differentiation rate of naïve Tregs into Treg~CM~ and/or a preferential infection and killing of Treg~CM~ \[[@R25]\]. Memory Tregs are in fact highly proliferative compared to their naïve counterparts, and in this situation, which favours viral replication \[[@R26]\], Treg~CM~could represent a population more prone to apoptosis \[[@R20]\]. Accordingly, we found that a higher viral load correlated with a lower percentage of Treg~CM~ (r=−0.51; p=0.016). Thus, an accelerated turnover of Treg~CM~ in conditions of high viral replication could drive a homeostatic expansion of naïve Tregs, whose proportion, in turn, was found to be positively correlated with the viremia (r=0.51; p=0.017). This interpretation implies the assumption that homeostatically expanded naive cells accumulated because unable to differentiate into memory cells, in contrast to what would be normally expected \[[@R27]\]. Indeed, whereas this process is normally dependent on IL-7 stimulation \[[@R27]\], in naive Tregs of viremic patients the downstream parts of IL-7 signalling machinery are known to be disrupted \[[@R28]\].

Alternatively, the reduced proportion of circulating Treg~CM~ in the blood of untreated patients could merely reflect an enhanced retention of this population in lymphoid organs. In fact, while Treg~CM~ and Treg~EM~ should not differ in terms of regulatory capacity \[[@R22]\], the differential expression of CCR7 empowers them to migrate to the lymphoid and the peripheral tissues, respectively, to perform their suppressive functions \[[@R22],[@R23]\]. In the lymphatic tissues, Treg~CM~ might underlie an increased immune suppression that would be responsible, on one hand, of a less efficient control of viral replication (shown by the residual viremia), and, on the other hand, of a lower degree of chronic immune activation, which, in turn, could explain the conserved CD4^+^ cell number present in the viremic patients even if untreated. Interestingly, this interpretation fits with observations made in African green monkeys infected by simian immunodeficiency virus \[[@R4]\].

Differently from the untreated, in the cART-treated patients the percentage of naïve and Treg~CM~ were similar to that of HD (in whom Treg~CM~is usually the most represented subset) \[[@R29]\]. In addition, only in treated patients and not in the untreated (data not shown), a highly significant, strong positive correlation between the percentage of naïve Tregs and the CD4^+^ cell count, and an inverse correlation between Treg~CM~and CD4^+^ cells were found (Fig. **[1F](#F1){ref-type="fig"}**). As already suggested by Simonetta *et al.* \[[@R17]\], this indicated that the relationship between naïve Tregs and the CD4^+^ cell count is restored by the long lasting cART. On the other hand, our data differ from those of the same authors reporting that the naïve-like Treg number was preserved in HIV-infected patients regardless of treatment \[[@R17]\]. This discrepancy could be explained either by the different methodological approaches, or by the different HIV plasma levels in the patients of the two studies. The strong correlation found between the percentage of naive Tregs and the viral load (r=0.51, p=0.016) supports the second hypothesis. Therefore, although performed with different methodological approaches and type of patients, our study, at least in part, complements that of Simonetta *et al.* \[[@R17]\] by demonstrating that a long lasting effective cART restores Treg homeostasis, most likely by hampering HIV replication in the periphery and into the lymphoid sanctuaries \[[@R30],[@R31]\].

It is also not straightforward to compare our results with those by Zhou *et al*. \[[@R24]\], who found that nTregs were greatly reduced while aTregs were increased in chronically infected, treatment-naive viremic patients (but not in those acutely-infected). Indeed, in the mentioned study patients were therapy-naive at the time of recruitment, and then started treatment because of disease progression, whereas our untreated patients were stable, chronically infected subjects never undergoing treatment throughout the study period. On the other hand, even if we could not perform a Treg quantification before treatment beginning, our findings in the long-term cART-treated patients are in agreement with those of Zhou *et al*. \[[@R24]\] in demonstrating that the extent of post-therapy nTreg recovery relied on the amount of CD4^+^ cell number before therapy. Indeed, by stratifying our patients in two groups on the basis of the routinely-tested pre-therapy CD4^+^ cell number, we found that the higher median percentage of both naive Tregs (33% *vs*23%, p=0.046) and nTregs (2.10% *vs*1.23%, p= 0.010) was measured in the group of patients with a baseline CD4^+^ cell count over 200 cells/µL.

In the context of our study, one concern may arise from the method employed to identify Treg cells, because the down-regulation of CD127 due to the HIV-induced chronic immune activation \[[@R32],[@R33]\] may lead to an overestimation of Tregs in viremic patients, when these cells are identified only according to the lack of CD127 and not to the presence of FOXP3 \[[@R8]\]. However, also the more commonly used Treg marker FOXP3 is transiently up-modulated after cell activation in a fraction of effector, non-regulatory cells \[[@R34]\], and FOXP3^+^CD25^+^CD45RA^−^ cells have also been reported to be non-regulatory \[[@R20]\]. Furthermore, even in viremic patients, the overwhelming majority of CD25^high^CD127^low^ cells have been shown to coincide with the FOXP3^high^ population \[[@R7]\]. To definitively rule out the possibility that our results could be technically biased, we analyzed the expression of the CD127 marker within the total naive and memory T-cell subsets. In contrast to the selective increase of CD127^low/−^ cells within the naive Treg subset and to their decrease within the Treg~CM~ or Treg~EM~ subsets in the untreated viremic patients (Fig. **[1C](#F1){ref-type="fig"}**), an increased frequency of CD127^low/−^ cells was found within the T~CM~ and T~EM~ subsets, but not within the naive one in the same patients (Fig. **[2](#F2){ref-type="fig"}**). This result indicates that the present findings are not an artefact mirroring the chronic immune cell activation typical of viremic patients, but are likely to represent a modulation of *bona fide* Treg cell subsets.

In conclusion, we propose that the redistribution of Treg subsets contributes to explain the partially preserved CD4^+^ cell counts despite the ongoing viremia seen in untreated patients. Therefore, an analysis of the fine modulation of the Treg subsets, rather than a study of the total Treg population, should be performed for a better understanding of the Treg role in HIV infection and therapy. However, the heterogeneity of HIV patients and methods advocates the need of further studies, aimed at identifying the most appropriate Treg definition in the different subsets of HIV patients.
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APPENDIX
========

![Quantification of the Treg subpopulations. A. CD4^+^ cells, gated on lymphocytes, were first analyzed for the expression of the CD25 and CD127 surface antigens (Tregs defined as CD4^+^CD25^+^CD127^low/−^). The subsequent phenotyping based on the expression of CD45RA and CCR7 on the Treg population, as shown in the representative plot, allowed the distinction of Tregs into naïve CD4^+^CD25^+^CD127^low/−^CD45RA^+^CCR7^+^, central-memory-like (TregCM) CD4+CD25+CD127^low/−^CD45RA−CCR7^+^ and effector memory-like (TregEM) CD4^+^CD25^+^CD127^low/−^CD45RA^−^CCR7^−^ populations. B. On CD4^+^ cells, naive-like nTregs were gated as CD45RA+CD25^+^ cells, and memory-like aTregs as CD45RA−CD25high cells. C. Percentage of Tregs with a naïve, TregCM, and TregEM phenotype in untreated (UNT), long-term combination antiretroviral therapy (cART)-treated patients, and healthy donors (HD). Horizontal lines indicate the significant differences between groups. The percentages of naïve Tregs, TregCM, and TregEM were also significantly different when compared within each group, exception made for the naïve Tregs and TregCM, which were not different within HD (significance lines not displayed). D. Quantification of nTregs and aTregs as a proportion of CD4+ cells in patients (UNT, cART) and HD. Horizontal lines indicate the significant differences between groups. E. Correlations between the measures of naive Tregs and nTregs in patients (UNT, cART) and HD. Lines obtained by linear regression analysis. F. Correlations between the Treg subsets and CD4+ cell counts in the cART-treated patients. Lines obtained by linear regression analysis. \*\*\*: p\<0.001; \*\*: p\<0.01; \*: p\<0.05.](TOAIDJ-8-1_F1){#F1}

![Expression of CD127 in non-regulatory T cell subsets. Percentages of CD127^low/−^ cells among naïve, TCM, and TEM CD4^+^ cells in untreated (UNT), long-term combination antiretroviral therapy (cART)-treated patients, and healthy donors (HD).](TOAIDJ-8-1_F2){#F2}

![Correlation between the percentage of memory Tregs (TregCM + TregEM) and aTregs in all patients and controls (A), in untreated patients (B), and in long-term treated patients (C). Lines are obtained by linear regression. UNT: untreated patients; cART: patients treated for more than 6 years with a combined antiretroviral therapy.](TOAIDJ-8-1_APF1){#APF1}

###### 

Immunological characteristics of included patients. Routine immunological and virological parameters of patients included in the study

                            UNT                   cART            p
  ------------------------- --------------------- --------------- ---------
  M:F                       17:5                  26:4            NS
  Mean age (range)          39 (23-54)            47 (36-58)      \<0.001
  CD4+ T cells (%)          30 (26-34)            32 (27-38)      NS
  CD4+ T cells (cells/µL)   538 (455-691)         688 (407-822)   NS
  CD4+/CD8+ T-cell ratio    0.7 (0.5-1)           0.8 (0.6-1.1)   NS
  HIV-1 RNA (copies/mL)     14 155 (263-33 380)   \<37 (37-37)    \<0.01

UNT: HIV-infected patients not needing treatment; cART: HIV-infected treated with cART for more than 6 years. p: p-value obtained by the Mann-Whitney test.
